Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPI Checkmate Pharmaceuticals	$10.50	$10.46	$2.00 ▼ $10.50	$231.40M	-4.81	142,261 shs	N/A
LIV Emles @Home ETF	$15.73	$15.73	$0.00 ▼ $0.00	N/A	N/A	N/A	3,055 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPI Checkmate Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LIV Emles @Home ETF	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPI Checkmate Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LIV Emles @Home ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPI Checkmate Pharmaceuticals	0.00	N/A	N/A	N/A
LIV Emles @Home ETF	0.00	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPI Checkmate Pharmaceuticals	N/A	N/A	N/A	N/A	$2.50 per share	N/A
LIV Emles @Home ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPI Checkmate Pharmaceuticals	-$61.40M	-$2.92	N/A	N/A	N/A	N/A	-83.92%	-74.99%	N/A
LIV Emles @Home ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPI Checkmate Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LIV Emles @Home ETF	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPI Checkmate Pharmaceuticals	N/A	5.20	5.20
LIV Emles @Home ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPI Checkmate Pharmaceuticals	74.56%
LIV Emles @Home ETF	N/A

Insider Ownership

Company	Insider Ownership
CMPI Checkmate Pharmaceuticals	62.60%
LIV Emles @Home ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPI Checkmate Pharmaceuticals	28	22.04 million	8.24 million	Not Optionable
LIV Emles @Home ETF	69,100	N/A	N/A	Not Optionable

DNE, OOA, CMPI, and LIV Headlines

Recent News About These Companies

Jiva Technologies Announces the Launch of www.LIV3Health.com, Kicking Off Presale Orders for Revolutionary SugarShield Supplement

January 28, 2025 | prnewswire.com

Jiva Technologies Initiates Production of LIV3's SugarShield Supplement with Best Formulations, Accelerating Path to Market for Innovative Wellness Support Solution

December 5, 2024 | prnewswire.com

DNE, OOA, CMPI, and LIV Company Descriptions

Checkmate Pharmaceuticals NASDAQ:CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Emles @Home ETF BATS:LIV

$15.72 0.00 (0.00%)

As of 10/19/2022

Autoliv, Inc., through its subsidiaries, develops, manufactures, and supplies passive safety systems to the automotive industry in Europe, the Americas, China, Japan, and rest of Asia. It offers passive safety systems, including modules and components for frontal-impact airbag protection systems, side-impact airbag protection systems, seatbelts, steering wheels, inflator technologies, and battery cut-off switches, as well as anti-whiplash systems and pedestrian protection systems, and connected safety services and solutions for riders of powered two wheelers. The company primarily serves car manufacturers. Autoliv, Inc. was founded in 1953 and is headquartered in Stockholm, Sweden.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time